The NIDA Avenir award in genetics or epigenetics of substance use disorders

John S Satterlee; Jonathan D Pollock; Nora D Volkow

doi:10.1016/j.mcn.2023.103899

The NIDA Avenir award in genetics or epigenetics of substance use disorders

Mol Cell Neurosci. 2023 Dec:127:103899. doi: 10.1016/j.mcn.2023.103899. Epub 2023 Sep 20.

Authors

John S Satterlee¹, Jonathan D Pollock², Nora D Volkow³

Affiliations

¹ National Institute on Drug Abuse, Three White Flint North, 11601 Landsdown Street, North Bethesda, MD 20852, United States of America. Electronic address: satterleej@nida.nih.gov.
² National Institute on Drug Abuse, Three White Flint North, 11601 Landsdown Street, North Bethesda, MD 20852, United States of America. Electronic address: jpollock@nida.nih.gov.
³ National Institute on Drug Abuse, Three White Flint North, 11601 Landsdown Street, North Bethesda, MD 20852, United States of America. Electronic address: nvolkow@nida.nih.gov.

PMID: 37739148
DOI: 10.1016/j.mcn.2023.103899

Abstract

NIDA's Avenir Program in the Genetics or Epigenetics of Substance Use Disorders (SUDs) was launched to support early stage investigators who propose innovative, high risk, but potentially high impact research and who show promise of being tomorrow's leaders in this scientific field. Since 2015, NIDA has supported 30 Avenir Investigators with unique expertise and creative ideas. This special issue showcases how some of these ideas have germinated, flourished, and borne fruit. In this perspective article we briefly describe the purpose and implementation of the Avenir award and provide a high altitude overview of the awardees and their scientific projects to date.

Publication types

Review

MeSH terms

Awards and Prizes*
Epigenesis, Genetic
Humans
Substance-Related Disorders* / genetics

Substances

N-nitrosoiminodiacetic acid